About FPR – Who We Are
Forerunner Pharma Research (FPR) is a joint venture founded in April 2005 by Chugai Pharmaceutical Co., Ltd. (Chugai), Mitsui & Co., Ltd. (Mitsui), and the Central Institute for Experimental Animals (CIEA). Earlier in 2002, the parties caused to form PharmaLogicals Research Pte. Ltd. (PLR) in Singapore, to pursue more effective approaches for antibody drug discovery by means of disease and gene analysis, pathophysiological studies and genome informatics.
With its own research base favorably located at the Komaba Open Laboratory of the University of Tokyo, FPR occupies an advantageous position in utilizing the latest findings of academic and other institutions. In addition, FPR is backed up with drug development technologies of Chugai, Mitsui's business development capability, and groundbreaking "in vivo" evaluation system based on CIEA's cutting edge technology to produce transgenic animal models for human diseases.
By capitalizing on all these resources and capabilities, FPR strives for discovering revolutionary new drugs that helps increase people's health and wellbeing.
About Chugai Pharmaceutical Co., Ltd. (Chugai)
Chugai Pharmaceutical Co., Ltd. (TSE code 4519), a Roche Group company, is one of Japan's leading pharmaceutical companies specializing in prescription medicines. With strong R&D orientation, Chugai is highly rated by medical professionals for its biotechnology-based product line. Specifically, Chugai focuses on developing therapeutic antibodies and molecular targeting drugs in low-molecular form mainly for oncology and lifestyle-related diseases.
